Curi Wealth Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Curi Wealth Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-70,795	Closed	-$216K	–	159
2023 Q4	$216K	Buy	70,795 +53	+0.1%	+$100	0.03%	152
2023 Q3	$102K	Buy	70,742 +10,700	+18%	+$20.7K	0.02%	150
2023 Q2	$150K	Sell	60,042 -21,000	-26%	-$57.4K	0.02%	167
2023 Q1	$217K	Buy	81,042 +33	+0%	+$159	0.03%	154
2022 Q4	$440K	Buy	81,009 +22,272	+38%	+$187K	0.06%	118
2022 Q3	$734K	Sell	58,737 -26,000	-31%	-$297K	0.12%	88
2022 Q2	$419K	Buy	+84,737	New	+$469K	0.08%	71

Other funds holding GTHX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Curi Wealth Management's GTHX Position: Q1 2024 in Review

Curi Wealth Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 70,795 shares — an estimated $216K sold.

Curi Wealth Management first reported a position in GTHX in Q2 2022 and held it in 7 quarters. The position peaked at $734K in Q3 2022. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

Curi Wealth Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Curi Wealth Management sold 70,795 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $216K.
Curi Wealth Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Curi Wealth Management's G1 Therapeutics, Inc. Common Stock position peaked at $734K in Q3 2022.
86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Curi Wealth Management's 13F filing for Q1 2024.